



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 6789

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

22 June 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the incidence and treatment of different types of cancer.

You asked:

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?

- Carboplatin (monotherapy or in combination with 5-FU)*
- Cisplatin (monotherapy or in combination with 5-FU)*
- Cetuximab with/without chemotherapy*
- Cetuximab with radiotherapy*
- Pembrolizumab monotherapy*
- Pembrolizumab with chemotherapy*
- Nivolumab*
- Docetaxel (monotherapy or in combination with 5-FU)*
- Fluorouracil (5FU)*
- Radiotherapy only*
- Other*

2. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer (squamous cell carcinoma)? If so, can you please provide the name of each trial along with the number of patients taking part?

3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?

- Aflibercept*
- Bevacizumab*
- Capecitabine*
- CAPIRI*
- CAPOX (XELOX)*
- Cetuximab in combination with FOLFIRI*

- *Cetuximab in combination with FOLFOX*
- *Cetuximab not in combination with FOLFIRI or FOLFOX*
- *Irinotecan only*
- *FOLFIRI*
- *FOLFOX*
- *Fluorouracil (5FU) only*
- *Oxaliplatin only*
- *Panitumumab in combination with FOLFIRI*
- *Panitumumab in combination with FOLFOX*
- *Panitumumab not in combination with FOLFIRI or FOLFOX*
- *Nivolumab*
- *Raltitrexed*
- *Ramucirumab*
- *Regorafenib*
- *Sorafenib*
- *Other SACT*

Trust response:

1.

Carboplatin (monotherapy or in combination with 5-FU) - 3

Cisplatin (monotherapy or in combination with 5-FU) - 4

Cetuximab with/without chemotherapy - 0

Cetuximab with radiotherapy - 0

Pembrolizumab monotherapy - 0

Pembrolizumab with chemotherapy - 0

Nivolumab - 0

Docetaxel (monotherapy or in combination with 5-FU) - 0

Fluorouracil (5FU) - 0

Radiotherapy only - 0

Other - 0

2. No we do not currently have any open for Squamous cell carcinoma or for head and neck trials.

3.

Aflibercept - 0

Bevacizumab - 0

Capecitabine - 8

CAPIRI - 16

CAPOX (XELOX) - 12

Cetuximab in combination with FOLFIRI - 18

Cetuximab in combination with FOLFOX - 1

Cetuximab not in combination with FOLFIRI or FOLFOX - 4

Irinotecan only - 0

FOLFIRI - 36

FOLFOX - 25

Fluorouracil (5FU) only - 0

Oxaliplatin only - 0

Panitumumab in combination with FOLFIRI - 0

Panitumumab in combination with FOLFOX - 2

Panitumumab not in combination with FOLFIRI or FOLFOX - 2

Nivolumab - 4

Raltitrexed - 3
Ramucirumab - 0
Regorafenib - 1
Sorafenib - 0
Other SACT - 40